Status:

RECRUITING

Carotid Revascularization With MicroNet Covered Stent Comparing Early Neurological Outcomes With Distal Versus Proximal EPS

Lead Sponsor:

Meshalkin Research Institute of Pathology of Circulation

Collaborating Sponsors:

Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

Chelyabinsk Regional Clinical Hospital

Conditions:

Patients With Aterosclerotic Carotid Stenosis

Symptomatic Patients (Stenosis > 50%)

Eligibility:

All Genders

45-80 years

Phase:

NA

Brief Summary

The SIBERIA study demonstrated a clear advantage of CGuard stent implantation over the existing classical stent when using a distal anti-embolic device. At the same time, there is no Level 1 evidence ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Consecutive patients 45-80 years old accepted for CAS following neurological consultation and qualification for the procedure according to center's routine practice.
  • More than 6-month life expectancy
  • Suitable clinical conditions for performing DW-MRI
  • Written Informed consent approved by the Ethics Committee
  • Subject agrees to all required follow-up procedures and visits
  • Exclusion Criteria:
  • Currently enrolled in another investigational device or drug study that has not completed the study or that clinically interferes with the current study endpoints
  • Recent surgical procedure within 30-days before or planned surgery within 30-days after the stenting procedure
  • Hepatic active disease (bilirubin\> 35 mmol / l) or renal insufficiency (serum creatinine \> 2.5 mg/dL or glomerular filtration rate \<60 ml / min)
  • Recent evolving acute stroke within 30-days of study evaluation
  • Myocardial infarction within 72 hours prior to carotid stenting procedure (CPK-MB \> 3 times normal)
  • Female patients of childbearing potential or known to be pregnant
  • Any known factor for potential stroke other than carotid stenosis, such as atrial fibrillation or atrial flutter (paroxysmal, permanent or persistent) or thrombophilia
  • Patient on VKA or new oral anticoagulants

Exclusion

    Key Trial Info

    Start Date :

    November 1 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    January 1 2027

    Estimated Enrollment :

    366 Patients enrolled

    Trial Details

    Trial ID

    NCT05257161

    Start Date

    November 1 2021

    End Date

    January 1 2027

    Last Update

    February 25 2022

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    E. Meshalkin National Medical Research Center

    Novosibirsk, Russia